Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
NeoImmuneTech
Merck Sharp & Dohme LLC
Blanco, Dr Antonio Calles MD
Inspirna, Inc.
Sellas Life Sciences Group
European Organisation for Research and Treatment of Cancer - EORTC
Fate Therapeutics
Xencor, Inc.
Merck Sharp & Dohme LLC
Aeglea Biotherapeutics
Merck Sharp & Dohme LLC
Seoul National University Hospital